key: cord-0895777-bfpm36g6 authors: Gutiérrez, José María; Zanette, Larissa; Vigilato, Marco Antonio Natal; Pompei, Julio Cesar Augusto; Martins, Diogo; Fan, Hui Wen title: Appraisal of antivenom production in public laboratories in Latin America during the first semester of 2020: The impact of COVID-19 date: 2021-06-17 journal: PLoS Negl Trop Dis DOI: 10.1371/journal.pntd.0009469 sha: a83879b0bf3e79dcec5c420798beb70596cd149f doc_id: 895777 cord_uid: bfpm36g6 nan of development of therapeutic equine preparations against Severe Acute Respiratory Syndrome Coronavirus 2 (SARSAU : PleasenotethatSARS À CoV À 2hasbeendefinedasSevereAcuteRespira -CoV-2), preparation of diagnostic reagents, quality control activities, or assignment of staff to attend other pandemic issues? (c) Which are the priorities of the laboratories in the near future regarding regional cooperation in the field of antivenom manufacture and quality control? The survey was carried out between October 1 and October 19, 2020, using the platform Qualtrics (Qualtrics XM Platform, Seattle, Washington, United States of America). The responses to the survey are summarized as follows: a. A total of 357,266 vials of antivenoms were produced by these laboratories in this period. Seven laboratories manufactured antivenoms, whereas 5 laboratories did not. The reasons for halting the production in these cases were the need to carry out improvements in infrastructure for fulfilling the requirements of Good Manufacturing Practices (GMPs) in 4 cases and the restrictions to do face-to-face work in one institution. When compared to the same period during 2019, the volume of production increased in 2 laboratories, remained the same in 6 laboratories, and was reduced in 4 laboratories. An estimated average production of antivenoms in these institutions during the past years (adjusted for 6 months) was approximately 700,000 vials, based on the information provided by Fan and colleagues [6] . Hence, an overall reduction was observed for the region during the first half of 2020. b. Regarding the national demand of antivenom by national public health institutions, as compared to the same period in 2019, the demand increased for 3 laboratories, remained stable for 7 laboratories, and decreased for 2 of them. c. The laboratories attended various aspects related to the COVID-19 pandemics, as follows: (i) production of therapeutic equine-derived antibodies against SARS-CoV-2 (6 laboratories); (ii) production of diagnostic kits (2 laboratories); (iii) quality control activities (4 laboratories); and (iv) transfer of staff to other departments to attend issues related to the pandemics (7 laboratories). Two laboratories did not attend the COVID-19 emergency. d. Regarding the impact of COVID-19 on the antivenom manufacturing activities, 10 laboratories reported a drop in the personnel dedicated to antivenoms, 7 laboratories had a reduction in the acquisition of consumables for antivenom production, and 4 laboratories reported a reduction in the overall budget assigned to antivenom manufacture. e. In terms of the priority needs of the laboratories for the near future, the following aspects were identified in the survey: (i) implementation of a study on the preclinical efficacy of antivenoms distributed in Latin America; (ii) training of technical and professional staff in aspects related to antivenom production and quality control and implementation of GMPs; (iii) improvements in immunization schemes and innovations in the use of adjuvants; (iv) analysis of the situation of infrastructure and equipment in the laboratories; (v) pharmacovigilance of antivenoms; and (vi) translation to Spanish and Portuguese and distribution of the WHO guidelines for antivenom production and quality control [2] . The main conclusion from this survey is that, despite the crisis generated in the region by the COVID-19 pandemic, which has severely affected Latin America in terms of morbidity, mortality, and socioeconomic impact, the universe of public antivenom manufacturing laboratories has sustained its activity, albeit at a reduced level as compared to historical records [6] . Six laboratories maintained the production of 2019 and 2 increased their output, while 4 reported to have decreased their production. The drop in the output of antivenoms, as compared to the data provided by Fan and colleagues [6] , was mostly because several laboratories halted their production during the first half of 2020 for the reasons outlined above. Overall, the survey underscored the resilience of this regional collective of antivenom manufacturers in the context of the COVID-19 crisis while, at the same time, highlights the need to complete the improvements in various laboratories to resume the manufacture of antivenom once the infrastructure works are finished. Whether the fiscal crisis generated in these countries by the pandemics will delay these projects is unknown at present. It is noteworthy that the national demands of antivenoms by public health authorities (ministries of health and social security systems) in the countries where these manufacturers are located was reduced only in 2 cases, as compared to the same period in 2019. This suggests that public health authorities in the region have not neglected the relevance of snake bite envenoming, even during this unprecedented health and fiscal crisis. Whether this trend will continue is unknown, but it is expected that envenomings by animal bites and stings will receive the required attention by regional and national health authorities in Latin America in the coming years. It is of interest that 10 out of 12 institutions where antivenoms are manufactured attended in various ways the COVID-19 emergency. In particular, the regional efforts to generate horse-derived immunoglobulin preparations anti-SARS-CoV-2 for the treatment of the coronavirus infections are remarkable and derive from the long-standing regional tradition in the development and manufacture of antivenoms. Finally, the survey identified a series or priority actions required to improve the landscape of antivenom manufacture, control, and availability in the region. On the basis of this list of priorities, activities are being planned for the year 2021, including (i) the preparation of a research project to assess the preclinical efficacy of antivenoms, (ii) the translation of the WHO guidelines of antivenoms, together with the organization of remote teaching modules on the different aspects of these guidelines, to be offered to the laboratories of RELAPA, and (iii) the implementation of a technical consultation virtual platform for exchanges of information and expertise among RELAPA members in issues related to antivenom production. It is expected that these actions will strengthen the regional capacity for antivenom manufacture and control, with the consequent impact in the availability of this life-saving drug in Latin America. World Health Organization. Snakebite Envenoming. A Strategy for Prevention and Control. WHO, Geneva WHO Guidelines for the Production, Control and Regulation of Snake Antivenom Immunoglobulins Clinical and epidemiological aspects of scorpionism in the world: a systematic review Strengthening antivenom production in Central and South American public laboratories: report of a workshop Global availability of antivenoms: The relevance of public manufacturing laboratories Situació n de los laboratorios pú blicos productores de antivenenos en América Latina The SARS-CoV-2 pandemic in Latin America: the need for multidisciplinary approaches